Investigational Immunotherapy Treatments Offering Promise in Treating Pancreatic Cancer as Risk Factors Rise

PALM BEACH, Fla. , Sept. 26, 2023 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - There has been a rise in the prevalence of cancer in the past several years. Overall, there is a rapid increase in the prevalence of cancer cases and its growth is driven by factors such as unhealthy diet, physical inactivity, tobacco and alcohol consumption, air pollution and physical inactivity. Additionally, the incidence of cancer cases rises dramatically due to build up of cancer cases specific to age and the less effective repair mechanisms to be less effective as the person grows old. Additionally, the increase in chronic infections attributed as risk factors for cancer cases is rising, majorly in low-middle income countries. For instance, approximately 13% of cancers diagnosed in 2018 globally were attributed to carcinogenic infections, including Hepatitis C virus, HPV, and Epstein-Barr virus. Furthermore, according to oncology statistics, cancer cases are estimated to increase by 12.8 percent in 2025. As a result, rising cancer prevalence will increase the market's expansion. Globally, the pancreatic cancer market is increasing due to increasing cancer prevalence, rise in research and development, and a rising population. Additionally, cancer treatments are growing due to increasing funding and initiatives by government and private research organizations coupled with their collaborations with pharmaceutical companies is expanding the growth of the market. A report from Precedence Research projected that the global pancreatic cancer market size, which was estimated at USD 2.22 billion in 2022, is expected to be worth around USD 7.91 billion by 2032, growing at a remarkable CAGR of 13.6% between 2023 and 2032.  Active biotech and pharma companies in the markets this week include Oncolytics Biotech^® Inc. (NASDAQ:ONCY) (TSX:ONC.TO), Vaccitech plc (NASDAQ:VACC), Biophytis SA (NASDAQ:BPTS), TransCode Therapeutics, Inc. (NASDAQ:RNAZ), Bristol Myers Squibb (NYSE:BMY).